



## Development and Validation of a Stability Indicating Green Analytical Method for The Simultaneous Estimation of Ambroxol and Loratadine in Bulk and Pharmaceutical Dosage forms by RP-HPLC

S. Swarnalatha<sup>1</sup>, Narmada Vallakeerthi<sup>2</sup>, Swetha Gadthey<sup>3</sup> Kavitha Pingili<sup>1\*</sup>, P. Muralidhar Reddy<sup>3\*</sup>

<sup>1</sup>Department of Chemistry, Chaitanya (Deemed to be University), Warangal, Telangana 506001, India.

<sup>2</sup> Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, 500007, India.

<sup>3</sup>Department of Chemistry, University College of Science, Osmania University, Hyderabad 500007, India.

\*Corresponding author email: [kavithapingili04@gmail.com](mailto:kavithapingili04@gmail.com), [pmdreddy@gmail.com](mailto:pmdreddy@gmail.com)

### ABSTRACT

The reversed-phased high-pressure liquid chromatography (RP-HPLC) method for the estimation of Ambroxol (Amb) and Loratadine (Lora) in bulk drugs and pharmaceutical dosage forms has been developed, optimized, and validated. The flow rate of 1 ml/min was optimized and an injection volume of 20  $\mu$ L, the validated method evaluation was carried out using a Shimadzu RP-HPLC system, which was equipped with a symmetry column and detected using PDA (Photo diode array detector) detector at a wavelength of 246 nm. The mobile phase consisted of 0.1M potassium dihydrogen phosphate buffer with a pH adjusted to 6.2 using 0.1% orthophosphoric acid and acetonitrile in a 55:45, v/v ratio. Amb and Lora were found to have a retention time of 5.894 minutes, 3.202 minutes. The method was then validated using International Conference on Harmonization (ICH) Q2 R1 guidelines. The method has been validated for linearity, precision, accuracy and specificity and method was showing that linearity in a concentration of range of 15-90  $\mu$ g/ml for Amb and 1.25-7.5  $\mu$ g/ml for loratadine with correlation coefficients of  $r^2=0.999$ . Percentage recovery values were found to be 99.40%-99.42% for Amb and 99.11%-99.26% for Lora respectively. %RSD values of precision were determined to be 0.33% and 0.46%, correspondingly. The estimated limits of detection (LOD) for Amb and Lora were determined to be 0.03  $\mu$ g/ml and 0.7  $\mu$ g/ml, respectively, while the limits of quantification (LOQ) for Amb and Lora 2.18  $\mu$ g/ml and 0.09  $\mu$ g/ml, respectively. The developed method was then performed for degradation and stability studies along with the green assessment. After running the proposed approach using tools like the AGREE software, it was determined to have a lower greenness score (0.72). According to the results, the suggested method is appropriate for Ambroxol and Loratadine estimation in combined dosage form along with the stability studies with green assessment and method can be reliably used in routine labs and quality control laboratories for determination of the content of both the drugs. The proposed method was accurate, precise, robust, economical, and reproducible.

**Keywords:** Ambroxol, Loratadine, ICH guidelines, retention time, green assessment.


Received 19.10.2023

Revised 20.10.2023

Accepted 04.12.2023

### INTRODUCTION

The alkaloid vasicine derivative ambroxol hydrochloride is derived from the plant *Vasaka-Adhatoda vasica* and is a powerful mucolytic drug that can induce thin abundant bronchial discharge, which helps with expectoration [1-3]. Through its mucolytic and mucokinetic actions, ambroxol hydrochloride depolymerizes lengthy mucopolysaccharide chains, causing them to fragment, and allowing for the expectoration of excessive secretions. Because it inhibits the release of harmful mediators and free oxygen radicals by phagocytosis, ambroxol hydrochloride also functions as a tissue protector [4-6]. Loratadine is an allergist's go-to medication since it blocks second-generation peripheral histamine H1-receptors. Atypical antipsychotic quetiapine is a distant relative, and it shares structural similarities with tricyclic antidepressants like imipramine. It wasn't until 1993 that loratadine hit the market, despite its 1981 discovery. The medicine is marketed for its non-sedating characteristics, is available as a generic version, and is on the List of Essential Medicines by the World Health Organization. An alternative formulation, pseudoephedrine/loratadine, is available; it is a decongestant. As a specific inverse agonist of peripheral histamine H1-receptors, the tricyclic antihistamine loratadine alleviates allergic reactions. A lot of the symptoms of an allergic reaction are caused by histamine [7-11], structures of Amb and Lora as shown in Figure 1.



**Fig. 1. Structure of Ambroxol and Loratadine**

Pharmaceutical companies and clinical research laboratories regularly do quantitative analysis of pharmaceutically active components, whether they are in pure forms or drug formulations. In recent times, researchers have shown a preference for adopting the principles of green analytical chemistry (GAC). The main objective of GAC is to reduce or eliminate the negative effects of chemical processes on the environment and promote sustainability at the molecular level. It is not unexpected that many industrial sectors presently prioritize the environmental friendliness of chemical processes due to the significant benefits they offer, such as cost reduction, increased production, and savings in time and resources. In the 1990s, Paul Anastas and John Warner authored the inaugural green chemistry manual, which presented a series of 12 green chemistry principles. These principles focused on the elimination or end of the use of harmful solvents in chemical processes and evaluations, as well as the prevention of residue formation resulting from these processes. Subsequently, Paul Anastas emphasized the necessity of integrating these 12 principles to mitigate the environmental impact of new procedures and analytical tools. Consequently, the development of analytical methods is currently one of the most actively researched and studied issues in the field of green chemistry. In 2013, Galuszka, Migaszewski, and Namienski revised the 12 principles of green chemistry to align more closely with green analytical chemistry. The study describes the 12 concepts of green analytical chemistry as significant. Greenness assessment methodologies, including the national environmental method index (NEMI), the analytical eco-scale assessment (ESA), AGREE—Analytical Greenness Metric Approach, and the green analytical process index (GAPI), by the 12 principles of green chemistry. The NEMI approach, while simple and straightforward to use, is less accurate than other methods and is considered the earliest. The ESA tool utilizes numerical final results to determine the most environmentally friendly method employed. Furthermore, it is uncomplicated and more precise compared to the NEMI. The GAPI and AGREE is a recently developed and comprehensive method that offers a more accurate assessment of greenness. This study applies AGREE Methodologies.

During all stages of pharmaceutical development, analytical procedures are necessary to characterize the drug component and the composition of the drug product. An analytical technique must be validated by the guidelines provided by the International Conference on Harmonisation once it has been created for its intended purpose. According to the ICH guideline Q1A on Stability Testing of New Drug Substances and Products, stability-indicating testing procedures must be validated before testing features that are expected to change during storage and impact quality, safety, and/or efficacy can be conducted. Drug analysis improvement increasing with the use of analytical technique called high-performance liquid chromatography. It is perfect for analyzing a wide range of drugs in pharmaceutical dosage forms and biological fluids due to its ease of use, high sensitivity, and specificity.

Thus, the current study's goal is to create stability-indicating analytical technique for drug quantification in their formulations. The first objective deals with the optimization of chromatographic conditions and validation of the stability indicating analytical method for parameters such as specificity, precision, accuracy, linearity and range, LOD, LOQ, Robustness, and stability studies. The second part includes its Greenness evaluation by Agree software.

An extensive literature survey revealed that many analytical methods have been reported for the quantitative analysis of ambro & Lora alone and also in combination with other drugs in pure drugs and marketed formulations like UV, RP-HPLC [12-20]. The main goal of the green analytical chemistry is to take into the consideration the amount and toxicity of reagents can reducing the environmental impact of the activities of analytical chemistry. Stability indicating green reverse phase method has not been reported in the literature for the analysis of Amb and Lora, therefore the aim of the present study was to develop and validate a simple, cost effective, rapid, selective, precise, facile, reproducible, accurate stability indicating green RP-HPLC method for the analysis of Amb and Lora in bulk and marketed formulations.

**MATERIAL AND METHODS**

Using a Waters Alliance 2695 model HPLC system with a 2998 model PDA detector and Empower 2 software for processing and data collection, an isocratic RP-HPLC technique was used. The stationary phase was a 150 mm x 4.6 mm ID, 5 µm Symmetry C<sub>18</sub> HPLC Column. The investigation makes use of an analytical balance, an ultrasonic bath sonicator, and Whatman filter paper No. 41.

*Reagents used*

Leeford Pharmaceuticals in India provided the ambroxol and loratadine. We bought HPLC-grade acetonitrile from Merck Specialties Private Limited in Mumbai, India. Water, potassium dihydrogen phosphate, and orthophosphoric acid were purchased from Rankem Ltd. in India and were of HPLC grade. India's Cadila Pharmaceuticals Limited is the source of the Lorfast-AM Tablets®.

*Preparation of mobile phase*

A precisely measured 0.1M potassium dihydrogen phosphate was made, and its pH was brought to 6.2 using 0.1% orthophosphoric acid. It was then put into a 1000 mL volumetric flask and combined with HPLC-grade acetonitrile in a 55:45 v/v ratio. Ultimately, a 0.45 µm membrane filter was used for filtration, and ultrasonication was employed to eliminate any residual gas.

*Preparation of Ambroxol and Loratadine mixed standard drug stock solutions*

To get a concentration of 600µg/mL of Ambroxol and 50µg/ml of Loratadine, 60 mg of Ambroxol and 5 mg of Loratadine were dissolved in 100 mL of the mobile phase and then thoroughly dissolved using sonication in a 100 mL volumetric flask.

*Preparation of linearity solutions*

The concentration of 15, 30, 45, 60, 75, and 90 µg/mL of Ambroxol and 1.25, 2.5, 3.75, 5, 6.5, and 7.5µg/mL of Loratadine was prepared for linearity respectively. Before being injected into the HPLC system, all of the aforementioned solutions were filtered using a 0.45 µm nylon membrane filter.

*Preparation of sample solution*

Each tablet of Lorfast-AM Tablets® contains 60 mg of Ambroxol and 5 mg of Loratadine was taken and weighed. Twenty Lorfast-AM Tablets® were weighed, then crushed, and combined in a mortar and pestle to create a powder. A precisely weighed amount of powder, equal to 60 mg of Ambroxol and 5 mg of Loratadine, was put into a 100 mL volumetric flask that had been cleaned and dried. After adding the mobile phase and fully dissolving it with sonication, the mixture was filtered through a 0.45 µm nylon membrane filter. The volume was then adjusted with the same mobile phase to obtain concentrations of 50µg of Loratadine and 600µg of Ambroxol per millilitre. To get 60µg/mL of ambroxol and 5µg/mL of loratadine solution, From the previously mentioned solution, 1 mL was pipetted out, transferred to a 10 mL volumetric flask, and diluted with the mobile phase until the desired level was reached.

**Standard and sample solution for assay studies**


Six injections of an aliquot of 20 µL of the standard and sample solutions, each containing 60 µg/mL of ambroxol and 5 µg/ml of loratadine solution, were injected in HPLC shown in Table 1.

*Results for assay studies***Table 1. Assay of Ambroxol and Loratadine**

Drug	Lorfast-AM Tablets® (mg)	Amount found*(mg)	Label claim %
Ambroxol	60	59.88	99.8
Loratadine	5	5.005	100.1

**RESULTS AND DISCUSSION***Method optimization*

Many combinations of mobile phase compositions and parameters were tested to optimize the RP-HPLC process. Using a Symmetry C<sub>18</sub> HPLC Column (150 mm x 4.6 mm ID, 5 µm) and a mobile phase consisting of 0.1M potassium dihydrogen phosphate buffer (pH adjusted to 6.2 with 0.1% orthophosphoric acid and HPLC grade acetonitrile in the proportion of 55:45, v/v) delivered at a flow rate of 1 mL/min to get better reproducibility and repeatability with wavelength at 246 nm, Column temperature was kept at 25°C, and Runtime was 12 minutes. Ambroxol and Loratadine showed a satisfactory separation and good peak symmetry. The retention times for ambroxol and loratadine were, respectively, 5.894 and 3.202 minutes. Figure 3 displays a typical chromatogram of the standard and sample solution of Loratadine and Ambroxol.



**Fig. 3. Chromatogram of standard and sample solution of Loratadine and Ambroxol.**

#### Method validation

The established RP-HPLC method was validated in compliance with ICH guideline Q2 (R1) for the linearity, accuracy, precision, robustness, specificity, reproducibility, sensitivity to obtain the correctness of the method for efficient quality control testing in the laboratory [21-31].

#### Performance calculations

The system suitability parameters of the suggested RP-HPLC technique for the simultaneous measurement of ambroxol and loratadine in bulk and tablet dosage form were calculated to perform performance calculations. The system suitability of the suggested RP-HPLC method, which is displayed in Table 2, is confirmed by the excellent results of the system suitability parameters for the simultaneous estimation of ambroxol and loratadine in bulk and tablet dosage form. All results fall within the acceptance limit.

**Table 2. Performance calculations and system suitability parameters of Ambroxol and Loratadine**

Parameters	Ambroxol	Loratadine	Acceptance limits
Retention time (min)	5.894	3.202	-----
Theoretical plates (N)	5812	3722	Not less than 2000
Asymmetry factor	1.1	1.11	Not more than 2
Resolution	10	More than 2	
Linearity range ( $\mu\text{g/mL}$ )	15-90	1.25-7.5	-----
Limit of detection (LOD) ( $\mu\text{g/mL}$ )	0.03	0.7	-----
Limit of quantification (LOQ) ( $\mu\text{g/mL}$ )	0.09	2.18	-----

#### Specificity

The study examined the impact of excipients and other additives often found in the combined dosage form of ambroxol and loratadine in optimal conditions and verified the absence of any interference.

## Linearity

The concentration of 15, 30, 45, 60, 75, and 90 µg/ml of Ambroxol and 1.25, 2.5, 3.75, 5, 6.5, and 7.5 µg/ml of Loratadine was prepared for linearity respectively. A 20 µL of each of the aforementioned solutions was injected three times into the HPLC apparatus. Analysis using least squares regression was done to determine the correlation coefficient, slope, and intercept. The calibration curve was constructed by plotting peak area versus concentration (µg/ml) is shown in Figure 4 and the regression equation was calculated and the results are presented in Tables 3 and 4. The correlation coefficient was 0.999 which is considered satisfactory.




Fig. 4. Standard calibration curves and overlay chromatogram of Ambroxol and Loratadine.

Table 3. Linearity of Ambroxol and Loratadine


Concentration of Ambroxol (µg/mL)	Peak Area	Concentration of Loratadine (µg/mL)	Peak Area
15	499220	1.25	84860
30	1011151	2.5	170342
45	1521175	3.75	256544
60	2047944	5	342364
75	2515843	6.25	421586
90	3024459	7.5	511803

Table 4. Optical and regression parameters of Ambroxol and Loratadine

Optical and regression parameters	Ambroxol	Loratadine
Detection wavelength (nm)	246	
Linearity range (µg/mL)	15-90	1.25-7.5
Regression Equation (y=mx+C)	33675x+1747	68025x+262.3
Slope (m)	33675	68025
Intercept (C)	1747	262.3

**Accuracy**

By using the usual addition method to calculate the recoveries of ambroxol and loratadine, the accuracy of the suggested method was calculated. The accuracy of the suggested method was reported in Figure 5 and Tables 5 and 6. The per-analyzed sample solution of Lorfast-AM® tablet powder was mixed with concentration levels of 50%, 100%, and 150% of the standard solution of ambroxol and loratadine to conduct recovery studies.



**Fig. 5. Accuracy chromatogram of Ambroxol and Loratadine**

**Table 5. Results of accuracy studies of Ambroxol**

Added level	Quantity Added	Quantity Determined	% Recovery	% Mean
50%	30	29.725	99.08	
50%	30	29.868	99.56	99.41
50%	30	29.877	99.59	
100%	60	59.677	99.46	
100%	60	59.622	99.37	99.42
100%	60	59.656	99.43	
150%	90	89.537	99.49	
150%	90	89.804	99.78	99.40
150%	90	89.047	98.94	

**Table 6. Results of accuracy studies of Loratadine**

Added level	Quantity Added	Quantity Determined	% Recovery	% Mean
50%	2.5	2.485	99.40	
50%	2.5	2.475	99.01	99.14
50%	2.5	2.475	99.01	
100%	5	4.943	98.86	
100%	5	4.967	99.34	99.26
100%	5	4.979	99.57	
150%	7.5	7.437	99.16	
150%	7.5	7.433	99.11	99.11
150%	7.5	7.429	99.06	

**Precision**

Six injections of homogeneous sample preparation were made into the HPLC system, comprising 60µg/mL of ambroxol and 5µg/mL of loratadine from a single batch sample solution. The results of the method precision of Ambroxol and Loratadine were reported in Table 7.

**Table 7. Precision of Ambroxol and Loratadine**



Ambroxol		Loratadine	
Concentration ( $\mu\text{g/mL}$ )	Peak Area	Concentration ( $\mu\text{g/mL}$ )	Peak Area
60	1992625	5	336142
60	1995024	5	335422
60	1981748	5	332875
60	1994655	5	334881
60	1982458	5	335687
60	1996541	5	332488
Average	1990509	Average	334583
SD	6633.41	SD	1532.86
RSD %	0.33	RSD %	0.46

*Limit of detection and Limit of quantitation*

The LOD & LOQ were calculated for AMB&LORA. The limit of detection was found to be  $0.03\mu\text{g/ml}$  for AMB and  $0.7\mu\text{g/ml}$  for LORA respectively. The limit of quantification was found to be  $0.09\mu\text{g/ml}$  for AMB and  $2.18\mu\text{g/ml}$  for LORA respectively. The LOD & LOQ values are shown in Table 2 respectively.

**Robustness**

There were no significant changes which were observed in the developed stability indicating method when the chromatographic conditions viz., Change in the flow rate & Composition of mobile phase were calculated for six injections of AMB & LORA samples. The robustness values and the % RSD results are mentioned in Table 8 and fig 6 and 7.

**Fig. 6. Robustness chromatogram for flow rate variations of Ambroxol and Loratadine****Fig. 7. Robustness chromatogram for mobile phase proportion variations of Ambroxol and Loratadine****Table 8. Robustness data of Ambroxol**




Variations in method parameters	Retention Time (mins)	Average peak area	System suitability parameters	
			Theoretical Plates	Asymmetry
Flow rate (0.9ml/min)	6.733	3586391	6065	1.21
Flow rate (1.1ml/min)	5.272	2807773	5276	1.18
-10%, v/v mobile phase	5.941	3188691	5410	1.20
+10%, v/v mobile phase	5.881	3209747	5838	1.19

**Table 9. Robustness data of Loratadine**

Variations in method parameters	Retention Time (mins)	Average peak area	System suitability parameters	
			Theoretical Plates	Asymmetry
Flow rate (0.9ml/min)	3.660	606040	4184	1.19
Flow rate (1.1ml/min)	2.870	475786	3423	1.18
-10%, v/v mobile phase	3.220	540453	3597	1.19
+10%, v/v mobile phase	3.213	538980	4004	1.16

**Forced Degradation Studies**

Both Ambroxol and Loratadine were subjected to force degradation conditions viz., acidic, alkaline, neutral, oxidation, photolytic, and thermal. The stress samples of all the degradation were diluted with the prepared diluent to obtain a final concentration of 60 µg/ml and 5µg/ml. The % degradation & % recovery both are calculated and the values are shown in Table 10 & Fig 8-12 respectively.

**Fig. 8. Chromatogram of acid hydrolysis degradation studies for Ambroxol and Loratadine****Fig. 9. Chromatogram of alkali hydrolysis degradation studies for Ambroxol and Loratadine****Fig. 10. Chromatogram of oxidative degradation studies for Ambroxol and Loratadine**






Fig. 11. Chromatogram of thermal degradation studies for Ambroxol and Loratadine




Fig. 12. Chromatogram of photolytic degradation studies for Ambroxol and Loratadine

Table 10. Results of stability indicating assay of Ambroxol and Loratadine

Degradation Condition	Drug Recovered %		Drug Decomposed %	
	Ambroxol	Loratadine	Ambroxol	Loratadine
Acid hydrolysis	96.90	92.87	3.10	7.13
Alkali hydrolysis	95.70	97.10	4.30	2.90
Oxidative degradation	91.50	96.30	8.50	3.70
Thermal degradation	92.88	97.31	7.12	3.69
Photolytic degradation	93.32	96.77	6.68	3.23

### Summary of Validation

Table 11- Summary of Validation

Parameters		AMB	LORA	Acceptance Criteria	
Specificity	Retention time	5.894 min	3.202 min	Specific	
Assay	% Assay			98-102%	
	% RSD			< 2%	
Linearity & Range	Concentration ( $\mu\text{g/ml}$ )	15-90 $\mu\text{g/mL}$	1.25-7.5 $\mu\text{g/mL}$	Linear	
	Correlation coefficient	0.999	0.999	$r^2 \geq 0.998$	
Accuracy	50 % (% Recovery)	99.41	99.14	98-102%	
	100 % (% Recovery)	99.42	99.26	98-102%	
	150 % (% Recovery)	99.40	99.11	98-102%	
Precision	(% RSD)	0.33	0.46	< 2%	
LOD ( $\mu\text{g/ml}$ )		0.03 $\mu\text{g/mL}$	0.70 $\mu\text{g/mL}$	LOD<LOQ	
LOQ ( $\mu\text{g/ml}$ )		0.09 $\mu\text{g/mL}$	2.18 $\mu\text{g/mL}$	LOQ>LOD	
Robustness	Flow rate (ml/min) Rt	0.9	6.733	3.660	Robust
		1.1	5.272	2.870	Robust
	Mobile phase composition Rt	-10	5.941	3.220	Robust
		+10	5.881	3.213	Robust
System suitability	Retention time	5.894	3.202	Resolution was good	

USP Plate count (N)	5812	3722	> 2000
Asymmetrical factor (ASM)	1.1	1.11	≤ 2.0
USP Resolution	10		> 1.5

### Evaluation of Greenness by AGREE SOFTWARE

The AGREE tool is utilized to assess the environmental sustainability of the existing methodology. AGREE is an analytical tool that may evaluate the environmental impact of analytical methods, regardless of the specific technique utilized. This tool was constructed utilizing the 12 key green analytical chemistry factors, which encompass sample preparation, derivatization, automation, simplicity, solvent toxicity, number of samples tested, number of components analyzed in a single test, energy consumption per analysis, and analysis time. The outcome is transformed into a scale ranging from 0 to 1. The greenness character of the present HPLC technique was assessed using this instrument. The results indicated that the devised approach is environmentally sustainable, achieving a score of 0.72 depicted in Fig no -13.



Figure 13 Agree Evaluation

### CONCLUSION

Conventional HPLC methods are mostly used in pharmaceutical analysis which have an increased negative impact on the environment. To reduce the impact on the environment, conventional use must be minimized and green methods must be focused. The present study focuses on the development and validation of the RP-HPLC method for simultaneous determination of Amb and Lora along with stability studies in combined dosage form using green assessment tools like AGREE. The developed, optimized, and validated method is economical, environment safe, simple, quick, precise, accurate, robust, etc. This is the first method that has been reported with green analysis of the developed and validated method for estimation of AMB & LORA in a combined form with good resolution, fast elution time, and good peak resolution. The present developed method can be easily applied for quality control tests and routine analysis of AMB & LORA in combined pharmaceutical formulations.

### REFERENCES

1. Jose Villacampa, Fernando Alcantar, Juan Manuel Rodriguez, Jose Manuel Morales, Jorge Herrera, Rosa Rosete. Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men Clin Ther. 2003; 25(8):2225-32.
2. Malerba M, Ragnoli B (2008), "Ambroxol in the 21st century: pharmacological and clinical update", Expert Opin Drug Metab Toxicol, 4 (8).90-98
3. Seifart C, Clostermann U, Seifart U, Müller B, Vogelmeier C, von Wichert P, Fehrenbach H (February 2005). "Cell-specific modulation of surfactant proteins by ambroxol treatment". Toxicology and Applied Pharmacology. 203 (1): 27-35.
4. Sanderson RJ, Paul GW, Vatter AE, Filley GF (1976). "Morphological and physical basis for lung surfactant action". Respiration Physiology. 27 (3): 379-92.
5. Kido H, Okumura Y, Yamada H, Mizuno D, Higashi Y, Yano M (2004). "Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential". Biological Chemistry. 385 (11): 1029-34.
6. McNeill A, Magalhaes J, Shen C, Chau KY, Hughes D, Mehta A, et al. (May 2014). "Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells". Brain. 137 (5): 1481-95.
7. Pons-Guiraud A, Nekam K, Lahovsky J, Costa A, Piacentini A (2006). "Emedastine difumarate versus loratadine in chronic idiopathic urticaria: a randomized, double-blind, controlled European multicentre clinical trial". European Journal of Dermatology. 16 (6): 649-54.
8. Church MK, Church DS (May 2013). "Pharmacology of antihistamines". Indian Journal of Dermatology. 58 (3): 219-24.
9. Bielory L, Lien KW, Bigelsen S (2005). "Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis". Drugs. 65 (2): 215-28.

10. Canonica GW, Blaiss M (2011). "Antihistaminic, anti-inflammatory, and antiallergic properties of the non-sedating second-generation antihistamine desloratadine: a review of the evidence". *The World Allergy Organization Journal*. 4 (2): 47-53.
11. Fumagalli F, Baiardini I, Pasquali M, Compalati E, Guerra L, Massacane P, Canonica GW (2004). "Antihistamines: do they work? Further well-controlled trials involving larger samples are needed". *Allergy*. 59 (Suppl 78): 74-7.
12. Syed Sara Afreen, Panikumar Durga Anumolu, Pulusu Veera Shakar, Jampana Rama Tulasi, Karuna Devi Barla and Vijaya Durga Dumpala. (2023). Discriminating derivative spectrophotometric concurrent quantification of loratadine and ambroxol in tablet dosage form. *IJPSR*, 14(7): 3470-3474.
13. Madhusudant Bachute, S.V.Shanbhag. (2017). Simultaneous Estimation of Loratadine and Ambroxol Hydrochloride from Tablet Dosage Form by HPLC Method. *Int. J. Pharm. Sci. Rev. Res.*, 45(2),40: 221-227
14. N. Mallikarjuna Rao and D. Gowri Sankar. (2016). Development and Validation of Stability-indicating RP-HPLC Method for the Estimation of Pseudoephedrine, Ambroxol and Desloratadine in Bulk and Tablet Dosage Forms. *Indian Journal of Pharmaceutical Sciences*. 78(4):492-497.
15. S.G.T. Sri Vardhini and B.Thangabalan. (2016). Method Development and Validation for Simultaneous Estimation of Ambroxol Hydrochloride and Loratadine in Tablet Dosage Form by RP-UHPLC. *Int. J. Adv. Res.* 4(9), 1291-1301.
16. K.S.Chakravarthi, N.Devanna. (2016). A Stability Indicating RP-HPLC method for the Simultaneous Estimation of Desloratadine, Ambroxol and Pseudoephedrine in Bulk and Pharmaceutical Dosage Form. *IOSR Journal of Applied Chemistry*, 9(12): 01-08
17. Sreedhar Lade and Y. Rajendra Prasad. (2015). A Validated Stability Indicating Rp-Hplc Method for Estimation of Pseudoephedrine, Ambroxol and Desloratidine in Bulk and Pharmaceutical Dosage Form. *Int. J. Adv. Pharm. Biotech.*, 1(1): 1-19.
18. K. Anandakumar, P. Veerasundari. (2014). Simultaneous Estimation of Paracetamol, Ambroxol Hydrochloride, Levocetirizine Dihydrochloride, and Phenylephrine Hydrochloride in Combined Tablet Formulation by First-Order Derivative Spectrophotometry. *International Scholarly Research Notices*, Article ID 248960, 8 pages.
19. Sharma, D., G. Singh, D. Kumar, and M. Singh. (2014). Development And Validation of Spectroscopic Method for Simultaneous Estimation of Salbutamol Sulphate, Ambroxol Hydrochloride and Cetirizine Hydrochloride in Combined Pharmaceutical Tablet Formulation: A Novel Technique for In-Vitro Dissolution Studies. *International Journal of Pharmacy and Pharmaceutical Sciences*, 6(11): 446-52,
20. Muralidharan S, Kumar JR, Dhanara SA. (2013). Development and validation of a high-performance liquid chromatographic, and a ultraviolet spectrophotometric method for determination of Ambroxol hydrochloride in pharmaceutical preparations. *J Adv Pharm Technol Res*. 4(1):65-8.
21. Sanjeev, S. Bhaskar, Narmada Vallakeerthi, M. Kavitha, Anren Hu, P. Muralidhar Reddy, (2020). Development and Validation of RP-HPLC Method in Simultaneous Estimation of Lamivudine and Abacavir as Tablet Dosage Form, *Journal Of Critical Reviews*, VOL 7, ISSUE 02, 20-24
22. S. Bhaskar, Narmada Vallakeerthi, A. Sanjeev, M. Kavitha, D. Suman, and P. Muralidhar Reddy, (2023). A study on the development and validation of RP-HPLC method for the simultaneous estimation of Emtricitabine, Tenofovir Disoproxil Fumarate, and Efavirenz in both bulk and pharmaceutical formulations, *Eur. Chem. Bull.* 12(Special Issue 4), 886-900.
23. V. Narmada, A. Sanjeev, D.Suman, A. Ravinder Nath, P. Muralidhar Reddy, (2023). RP-HPLC Method Development, Validation Including Stability Indicating and Forced Degradation Studies for the Estimation of Pemetrexed in API and Pharmaceutical Dosage Form. *J. Phys. Conf. ser.* 2603; 012055. doi: 10.1088/1742- 6596/2603/1/012055.
24. Sanjeev, Narmada Vallakeerthi, N. Naresh Reddy, S. Bhaskar, P. Muralidhar Reddy, (2022). stability indicating method development and validation, stress degradation studies for dacarbazine by using RP-HPLC, *Neuro Quantology | Volume 20 | Issue 9 | Page 6270-6278 | doi: 10.14704/nq.2022.20.9.NQ44735*
25. Swetha Gadthey, Revathy Sundara Moorthy, Rohini Rondla, Narmada Vallakeerthi, P. Muralidhar Reddy, (2023). Development and Validation of Stability Indicating RP-HPLC Method for Simultaneous Determination of Anti-Haemorrhagic Ethamsylate and Anti-Fibrinolytic Tranexamic Acid in Combined Formulation using Green Assessment, *Journal of Chemical Health Risks, JCHR*; 13(4), 1084-1103 | ISSN:2251-6727.
26. Vallakeerthi, N., & Nath, A. R. (2021). Method development, validation, identification and quantification of residual solvents in phenazopyridine hydrochloride using head space-gas chromatography technique. *AIP Conference Proceedings*. <https://doi.org/10.1063/5.0061255>
27. Vallakeerthi, D. M. N. (2018). Development And Validation of a Rp - Hplc Method for The Simultaneous Determination Of Netupitant And Palonosetron In Pure And Pharmaceutical Dosage Form. *Zenodo (CERN European Organization for Nuclear Research)*. <https://doi.org/10.5281/zenodo.7066783>
28. Analytical Method Development and Validation or Simultaneous Estimation of Olmesartan and Rosuvastatin in Pure and Pharmaceutical Dosage Form by Using Rp-Hplc. (2023b). *International Journal of Biology, Pharmacy and Allied Sciences*, 12(10). <https://doi.org/10.31032/ijbpas/2023/12.10.7466>
29. Narmada Vallakeerthi, Rachala Swetha a, T. Tejaswi a, A. Ravinder Nath a, K. Bhavyasri b, N. Naresh Reddy ca and P. Muralidhar Reddy, (2023). Development and Validation of RP-HPLC Method for the Simultaneous Estimation of Bilastine and Montelukast in Tablet Dosage Form, *Chemical Science International Journal*, Volume 32, Issue 3, Page 52-61, Article no. CSIJ.99455 ISSN: 2456-706X
30. Vallakeerthi, N., Sanjeev, A., Suman, D., Nath, A. R., & Reddy, P. M. (2023c). RP-HPLC Method Development, validation including stability indicating and forced degradation studies for the estimation of pemetrexed in API

and pharmaceutical dosage form. *Journal of Physics: Conference Series*, 2603(1), 012055. <https://doi.org/10.1088/1742-6596/2603/1/012055>

31. Narmada Vallakeerthi, A. Ravinder Nath, Revathy Sundara Moorthy, P. Muralidhar Reddy, (2022). HS-GC-FID Method Development and Validation for Quantification of Residual Solvents in Favipiravir, *Journal of Pharmaceutical Negative Results* | Volume 13 | Special Issue 10 | 20-25

#### **CITATION OF THIS ARTICLE**

S. Swarnalatha, Narmada V, Swetha G, Kavitha P, P. Muralidhar Reddy. Development and Validation of a Stability Indicating Green Analytical Method for The Simultaneous Estimation of Ambroxol and Loratadine in Bulk and Pharmaceutical Dosage forms by RP-HPLC. *Bull. Env. Pharmacol. Life Sci.*, Vol 13 [1] December 2023: 129-140.